Purpose This study aimed to investigate the possible effects of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.
Introduction
The direct renin inhibitor aliskiren is poorly absorbed and has a low oral bioavailability of 2-3% [1] . Aliskiren is mainly eliminated by biliary excretion [1] . In addition, about 0.4% of the oral dose is excreted unchanged into urine and about 1.4% undergoes oxidative biotransformation via CYP3A4 [1] . Aliskiren is a substrate of Pglycoprotein (also known as ABCB1) [2] , an efflux transporter expressed in tissues with an excretory or barrier function [3, 4] . The P-glycoprotein and CYP3A4 inhibitors, itraconazole and cyclosporine [5] [6] [7] [8] [9] , have raised the area under the plasma concentration-time curve (AUC) of aliskiren by about 6.5-fold and 5-fold respectively [10, 11] , supporting a major role of P-glycoprotein in limiting the intestinal absorption of aliskiren. Moreover, rifampicin, an inducer of P-glycoprotein and CYP3A4 [12, 13] , has reduced the AUC of aliskiren by 56% [14] .
A common synonymous single nucleotide polymorphism (SNP) in the ABCB1 gene encoding P-glycoprotein, c.3435C>T, has been variably associated with reduced expression and function of P-glycoprotein in vitro and increased plasma concentrations of P-glycoprotein substrate drugs in vivo [15] [16] [17] . The mechanism underlying these associations is not completely understood, but it has been suggested that c.3435C>T affects ABCB1 mRNA stability [18] . Alternatively, the associations may be explained by linkage disequilibrium between c.3435C>T and a functional sequence variation, or that c.3435C > T and sequence variations in linkage disequilibrium with it form a haplotype conferring altered P-glycoprotein activity [16, 19] . The ABCB1 c.3435C>T SNP is in strong linkage disequilibrium with the c.1236C>T (synonymous) and c.2677G>T/A (p.Ala893Ser/Thr) SNPs within the same gene [17, 19, 20] .
The variant alleles c.1236T, c.2677T, and c.3435T are common in Europeans and European Americans, with reported frequencies of occurrence ranging from 39 to 46%, 39 to 47%, and 54 to 60% respectively [17, [19] [20] [21] [22] . In the Finnish population, the two most common haplotypes based on these SNPs are c.1236T-c.2677T-c.3435T (TTT) and c.1236C-c.2677G-c.3435C (CGC), with frequencies of 42.7% and 34.4% respectively [17] . The ABCB1 TTT haplotype has been associated, for example, with increased plasma concentrations of and enhanced lipid-lowering response to simvastatin (acid) and atorvastatin, compared with the ABCB1 CGC haplotype [17, 23, 24] .
Considerable interindividual variability exists in the pharmacokinetics of aliskiren [25] , but the background of this variability is unknown. Our hypothesis was that genetic variability in ABCB1 affects the pharmacokinetics of aliskiren. Therefore, we investigated the effects of the ABCB1 CGC and TTT haplotypes on the pharmacokinetics and pharmacodynamics of aliskiren.
Materials and methods

Subjects
Twenty-two healthy white Finnish volunteers participated in this study after having given written informed consent. They were recruited from a group of more than 700 subjects genotyped for the ABCB1 c.1236C > T (rs1128503), c.2677G>T/A (rs2032582), and c.3435C>T (rs1045642) SNPs [17] . To minimize variability in aliskiren pharmacokinetics due to other genetic variants, all subjects were genotyped for the functionally significant ABCB1 c.1199G > A (p.Ser400Asn; rs2229109) [17] and CYP3A5*3 (g.6986A>G; rs776746) [26] alleles and only noncarriers of the ABCB1 c.1199A and CYP3A5 g.6986A (CYP3A5 expressor) alleles were recruited.
Four women and 7 men homozygous for the ABCB1 CGC haplotype, mean ± SD age 26±4 years (range, 22-37 years), height 178±9 cm (158-189 cm), and weight 74± 11 kg (63-95 kg), and 5 women and 6 men homozygous for the TTT haplotype, age 24±2 years (21-27 years), height 175±10 cm (158-186 cm), and weight 69±12 kg (51-94 kg), participated in the study. Each participant's health was ascertained by medical history, clinical examination, and laboratory tests. None was on any continuous medication and none was a tobacco smoker.
Study design
The study protocol was approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District, and the National Agency for Medicines. Following an overnight fast, the subjects ingested a single 150-mg dose of aliskiren (Rasilez; Novartis, Horsham, UK) with 150 ml water. A standardized warm meal was served 4 h after aliskiren, and a standardized light meal after 7 h and 10 h. As a safety assessment, systolic and diastolic blood pressures were measured from the forearm with an automatic oscillometric blood pressure monitor (Omron M5-I; Omron Healthcare Europe BV, Hoofddorp, The Netherlands), with the participant in a sitting position, prior to and 2, 4, 7, 9, 12, and 24 h after aliskiren ingestion. The participants were under direct medical supervision for 12 h after the administration of aliskiren. No significant differences in blood pressure were observed between the haplotype groups (data not shown). Use of other drugs was prohibited for 1 week and use of grapefruit products for 3 days before aliskiren administration and 3 days thereafter.
Timed blood samples (5 or 10 ml each) for aliskiren concentration measurements were drawn into tubes containing ethylenediaminetetraacetic acid (EDTA) prior to and 0.5, 1, 2, 3, 4, 5, 7, 9, 12, 24, 34, 48, and 72 h after aliskiren administration. Blood samples for the determination of plasma renin activity (5 ml each) were drawn before the administration of aliskiren and 4 h and 24 h thereafter into chilled EDTA tubes, which were placed on ice immediately after sampling. Plasma was separated within 30 min. Urine was collected up to 12 h after aliskiren ingestion. Urine aliquots and plasma were stored at −70°C until analysis.
Determination of aliskiren concentrations and renin activity
Plasma concentrations of aliskiren were quantified by use of solid phase extraction and liquid chromatographytandem mass spectrometry (LC/MS/MS) [10] . An aliquot of 700 µl of each plasma sample was mixed with 100 µl of 10% phosphoric acid and 50 µl internal standard solution (1,000 ng/ml acebutolol in 1:1 methanol:water). Then the mixture was loaded to the extraction cartridge (Oasis MCX 1 cc/30 mg; Waters, Milford, MA, USA), which had been pre-conditioned with 1 ml of methanol and 1 ml of 1% acetic acid. The cartridge was subsequently washed with 1 ml of methanol and 1 ml of 1% acetic acid. The analytes were eluted out with two times 0.6 ml of 2% ammonium hydroxide in methanol. The eluent was dried at 50°C under a nitrogen stream. The residue was dissolved in 100 µl of the mobile phase, and 15 µl of the sample was injected into the LC/MS/MS system. The chromatographic separation was carried out on an AtlantisT3 column (2.1×100 mm, 3 µm) protected by an AtlantisT3 (2.1×10 mm, 3 µm) guard cartridge (Waters). The mobile phase consisted of (A) 2 mmol/l ammonium acetate (pH 4.90) and (B) methanol. The total running time was 15 min with the mobile phase gradient of 0.5 min at 70% A, 0.5 min to 5% A, 3 min at 5% A, 0.1 min to 70% A, and 10.9 min at 70% A. The flow rate of the mobile phase was 250 µl/min. The column temperature was 40°C. Mass spectra were obtained using an Applied Biosystems SCIEX API 2000 Q Trap mass spectrometer operated in positive ion mode (Sciex Division of MDS, Toronto, ON, Canada). The ion transitions were mass-to-charge ratio (m/z) 552. 4 
For the determination of aliskiren concentrations in urine, an aliquot of 300 µl of each urine sample was mixed with 300 µl of fresh frozen plasma, 100 µl of 10% phosphoric acid, and 50 µl internal standard solution (1,000 ng/ml acebutolol in 1:1 methanol:water). The extraction, chromatographic separation, and mass spectrometric detection were performed as described for plasma aliskiren. The lower limit of quantification was 0.25 ng/ml for plasma and 9 ng/ml for urine aliskiren. The calibration curve for plasma aliskiren was linear over the range 0.25-500 ng/ml (r>0.999, weighting 1/x) and for urine aliskiren over the range 9-1,800 ng/ml (r>0.999, weighting 1/x). The extraction recoveries were > 80%. The intra-day coefficients of variation were ≤ 1.2% at relevant concentrations in plasma and ≤ 4.8% in urine (n=6). Plasma renin activity was determined by radioimmunoassay of generated angiotensin I with a commercially available method (RENCTK; DiaSorin, Saluggia, Italy) at HUSLAB laboratory (Helsinki, Finland).
Pharmacokinetics and pharmacodynamics
Aliskiren pharmacokinetics were characterized by peak plasma concentration (C max ), time to C max (t max ), elimination half-life (t ½ ), AUC 0-72 , AUC 0À1 , the amount of aliskiren excreted into urine from 0 to 12 h (Ae), and the renal clearance (Cl renal ). Pharmacokinetic parameters were calculated with non-compartmental methods using MK-Model, version 5.0 (Biosoft, Cambridge, UK). The terminal loglinear part of each concentration-time curve was identified visually. The elimination rate constant (k e ) was determined by linear regression analysis of the log-linear part of the plasma drug concentration-time curve. The t ½ was calculated by the equation t ½ =ln2/k e . The AUC values were calculated by a combination of the linear and log-linear trapezoidal rules with extrapolation to infinity, when appropriate, by division of the last measured concentration by k e . The Cl renal of aliskiren was calculated by the equation Cl renal =Ae/ AUC 0-12 . Aliskiren pharmacodynamics were characterized by plasma renin activity at 4 h and 24 h after aliskiren intake.
Statistical analysis
The data were analyzed using SPSS 17.0 (SPSS, Chicago, IL, USA). The C max , AUC, Ae, and Cl renal data were logarithmically transformed before statistical analysis. Statistical comparisons were made between the ABCB1 haplotypes using analysis of variance (ANOVA). Body C max , AUC, and Ae data are estimated marginal mean (95% CI) adjusting for weight; t ½ , Cl renal , and plasma renin activity are estimated marginal mean (95% CI); t max are median (range). CI, confidence interval; C max , peak plasma concentration; t max , time to C max ; t ½ , elimination half-life; AUC 0-72 , area under the plasma concentration-time curve from 0 to 72 h; AUC 0À1 , area under the plasma concentration-time curve from time 0 to infinity; Ae, amount excreted into urine within 12 h; Cl renal , renal clearance; baseline, before the administration of aliskiren *Mean difference (95% CI)
weight was set as a covariate for C max , AUC, and Ae [27] . The t max data were compared with the Mann-Whitney test. Differences were considered statistically significant when P<0.05. The geometric mean ratio between the TTT and CGC homozygotes with 95% confidence interval (CI) was calculated for the C max , AUC, Ae, and Cl renal values, and the mean difference with 95% CI for the t ½ and renin activity variables. The number of subjects was estimated to be sufficient to detect a 50% difference in the AUC 0À1 of aliskiren between the ABCB1 CGC and TTT homozygotes, with a power of 80% (α-level 5%).
Results
ABCB1
haplotypes had no significant effect on the pharmacokinetics or renin-inhibiting effect of aliskiren (Table 1 , Fig. 1 
Discussion
In the present study, the ABCB1 haplotypes had no significant effect on the pharmacokinetics or renin-inhibiting effect of the P-glycoprotein substrate aliskiren. However, these genetic results do not indicate that the P-glycoprotein transporter could not be otherwise important for the pharmacokinetics of aliskiren. In vitro, aliskiren is a high affinity substrate of P-glycoprotein (K m 2.1 μmol/l), as demonstrated by studies in P-glycoprotein-expressing Sf9 cell membrane vesicles [2] . In vivo, inhibitors and inducers of P-glycoprotein markedly affect aliskiren pharmacokinetics [10, 11, 14] . It is noteworthy that ABCB1 genotypes have explained only a fraction of the variability in P-glycoprotein expression, and the effects of ABCB1 genotypes and haplotypes on drug pharmacokinetics have been modest [15, 17, 28, 29] . For example, the AUCs of simvastatin acid and atorvastatin have been 60% and 55% larger respectively in subjects homozygous for the ABCB1 TTT haplotype compared with subjects homozygous for the CGC haplotype [17] . Studies investigating the effects of the ABCB1 c.3435C>T SNP on the pharmacokinetics of the P-glycoprotein prototype substrate digoxin have revealed conflicting results, with a metaanalysis suggesting that the ABCB1 c.3435C>T SNP does not affect digoxin pharmacokinetics [12, 15, [28] [29] [30] [31] . It has been suggested that the ABCB1 c.3435C>T SNP, or its combination with the c.1236C>T or c.2677G>T/A SNP, may alter the substrate specificity of P-glycoprotein [16] . Therefore, the effect of the ABCB1 genotype on the pharmacokinetics of different P-glycoprotein substrates may vary.
The present study had sufficient power to detect a 50% difference in the AUC 0À1 of aliskiren between ABCB1 haplotypes, and thus a small difference cannot be ruled out. However, it is unlikely that a smaller than 50% difference in aliskiren AUC 0À1 would be of clinical importance. For example, a 76% increase in aliskiren AUC by ketoconazole was not considered clinically relevant [2] . Nevertheless, the mean AUC 0À1 values of aliskiren were almost identical in the two haplotype groups.
Similarly to previous reports [25] , a high interindividual variability was observed in the C max and AUC values of aliskiren. The present results suggest that common ABCB1 haplotypes do not explain this variability. The large differences in aliskiren pharmacokinetics might be explained by variability in gastrointestinal physiology, and other genetic and non-genetic factors affecting the activity of P-glycoprotein or CYP3A, or other transporters or enzymes involved in aliskiren pharmacokinetics [2] .
In conclusion, the common ABCB1 haplotypes c.1236C-c.2677G-c.3435C and c.1236T-c.2677T-c.3435T have no effects on the pharmacokinetics or pharmacodynamics of aliskiren.
